ONCOLOGIC OUTCOMES OF BLADDER-SPARING MANAGEMENT FOR HIGH-GRADE NON-INVASIVE UROTHELIAL CARCINOMA OF THE PROSTATIC URETHRAAlexander C. Martin, Vignesh T. Packiam, Ian M. McElree et al.|Urologic Oncology Seminars and Original Investigations|2024Cited by 2
Bladder-sparing management for high grade noninvasive urothelial carcinoma of the prostateAlexander C. Martin, Vignesh T. Packiam, Ian M. McElree et al.|Urologic Oncology Seminars and Original Investigations|2025Cited by 1
Long-term follow-up of intravesical gemcitabine and docetaxel as rescue therapy for nonmuscle-invasive bladder cancer.Phani T. Chevuru, Vignesh T. Packiam, Ian M. McElree et al.|Journal of Clinical Oncology|2022Cited by 0
Sequential intravesical gemcitabine and docetaxel for BCG-naïve high-risk nonmuscle-invasive bladder cancer.Ian M. McElree, Vignesh T. Packiam, Ryan L. Steinberg et al.|Journal of Clinical Oncology|2022Cited by 0
PD26-03 SEQUENTIAL INTRAVESICAL GEMCITABINE AND DOCETAXEL FOR BCG-NAïVE HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCERIan M. McElree, Vignesh T. Packiam, Ryan L. Steinberg et al.|The Journal of Urology|2022Cited by 0